ClinicalTrials.gg
RecruitingNCT07030712Updated Oct 13, 2026

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

A Phase 1 interventional study of MK-8294 and MK-8294 in Metastatic Neoplasm, sponsored by Merck Sharp & Dohme LLC. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 13, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 22 studies in Neoplasm Metastasis by Merck & Co., Inc — 2 open to participants now, 4 under way, 1 of them phase 3. Neoplasm Metastasis · Merck & Co., Inc.

Planned enrollment
11th of 22
67 · median 63
Started
2025
with 2 others
Phase 1
12 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies in Neoplasm Metastasis by Merck & Co., Inc, this one is the 11th largest by planned enrollment, is one of 3 that started in 2025, is one of 12 in phase 1, and was the 22nd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

2 of the 22 studies in Neoplasm Metastasis by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Neoplasm Metastasis by Merck & Co., Inc, or all of them as a file.
02

Study summary

MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.

03

Conditions studied

  • Metastatic Neoplasm

Keywords

  • Metastases
  • Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has or cytologically confirmed advanced/ solid tumor; including head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, breast cancer (triple negative breast cancer, Estrogen Receptor [ER]/progesterone receptor +, human epidermal growth factor receptor 2 negative [-]), endometrial, and bladder cancer by pathology report and have previously failed standard treatment, lack standard treatment options, or are intolerant to standard treatment
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has a history of Class II or greater heart failure
  • Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
  • Has ongoing radiation-related toxicities, requiring
  • Has known additional that is progressing or has required active treatment within the past 2 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has active disease that has required systemic treatment in the past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)
  • Has active infection requiring systemic therapy
  • Has history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or have ongoing surgical complications
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    MK-8294

    Participants will receive MK-8294 monotherapy in escalating doses starting from 30 µg up to a planned 70 mg via intravenous (IV) infusion. In addition, intermediate doses may also be assessed. MK-8294 will be administered on Day 1, Day 8, and Day 15 of each cycle (each cycle = 21 days). Per protocol treatment of MK-8294 has no maximum number of cycles. Participants will be treated until any of the criteria for discontinuation of study intervention are met. Participants may also receive a cluster of differentiation 8 (CD8) positron emission tomography (PET) tracer as a part of optional PET imaging.

    Drug: MK-8294 · Other: CD8 PET Tracer

Interventions

  • DrugMK-8294

    30 µg via intravenous (IV) infusion

    Also known as: DAB014236

  • DrugMK-8294

    100 µg via intravenous (IV) infusion

    Also known as: DAB014236

  • DrugMK-8294

    300 µg via intravenous (IV) infusion

    Also known as: DAB014236

  • DrugMK-8294

    1 mg via intravenous (IV) infusion

    Also known as: DAB014236

  • DrugMK-8294

    3 mg via intravenous (IV) infusion

    Also known as: DAB014236

  • DrugMK-8294

    10 mg via intravenous (IV) infusion

    Also known as: DAB014236

  • DrugMK-8294

    30 mg via intravenous (IV) infusion

    Also known as: DAB014236

  • DrugMK-8294

    70 mg via intravenous (IV) infusion

    Also known as: DAB014236

  • OtherCD8 PET Tracer

    IV Infusion

    Also known as: GEH200520 + GEH200521 (18F)

06

What researchers measure

Primary outcomes

  1. Number of participants who experience one or more dose-limiting toxicities (DLTs)

    DLT is defined as any drug-related adverse event (AE) observed during the DLT evaluation period (up to 35 days) that results in a change to a given dose or a delay in initiating the next treatment and reported as the number of participants experiencing a DLT.

    Time frame: Up to approximately 35 days

  2. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 2 years

  3. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study/study treatment due to an AE will be reported.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST). The percentage of participants who experience CR or PR as assessed by the investigator will be presented.

    Time frame: Up to approximately 2 years

  2. Area Under the Plasma Concentration-Time Curve (AUC) of MK-8294

    Blood samples collected pre-dose and at multiple timepoints post-dose will be used for the determination of Area Under the Concentration-Time Curve of MK-8294.

    Time frame: Predose and at designated timepoints in each cycle for up to approximately 2 years (each cycle = 3 weeks)

  3. Minimum Concentration (Cmin) of MK-8294

    Cmin is defined as the lowest concentration of MK-8294 after administration of MK-8294. Blood samples collected pre-dose and at multiple timepoints post-dose will be used for the determination of Cmin of MK-8294.

    Time frame: Predose and at designated timepoints in each cycle for up to approximately 2 years (each cycle = 3 weeks)

  4. Maximum Plasma Concentration (Cmax) of MK-8294

    Cmax is defined as the peak concentration of MK-8294 after administration of MK-8294. Blood samples collected pre-dose and at multiple timepoints post-dose will be used for the determination of Cmax of MK-8294.

    Time frame: Predose and at designated timepoints in each cycle for up to approximately 2 years (each cycle = 3 weeks)

  5. Time to Maximum Plasma Concentration (Tmax) of MK-8294

    Tmax is defined as the time to reach Cmax. Blood samples collected pre-dose and at multiple timepoints post-dose will be used for the determination of Tmax of MK-8294.

    Time frame: Predose and at designated timepoints in each cycle for up to approximately 2 years (each cycle = 3 weeks)

  6. Incidence of Antidrug Antibodies (ADA) to MK-8294

    Blood samples will be collected pre-dose and at designated time points to determine the ADA response to MK-8294. The incidence of ADAs over time will be presented.

    Time frame: Predose and at designated timepoints in each cycle for up to approximately 2 years (each cycle = 3 weeks)

  7. Titer of ADA to MK-8294

    Blood samples will be collected pre-dose and at designated time points to determine the ADA titers to MK-8294.

    Time frame: Predose and at designated timepoints in each cycle for up to approximately 2 years (each cycle = 3 weeks)

07

Study locations

8 of 8 sites recruiting
  • Northwestern University ( Site 0101)
    Chicago, Illinois 60611, United States
    Recruiting
    • Study Coordinator · Contact312-926-8105
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0105)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Study Coordinator · Contact551-996-5900
  • Houston Methodist Hospital ( Site 0103)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact346-238-4516
  • MD Anderson Cancer Center ( Site 0104)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact713-563-1930
  • Rambam Health Care Campus ( Site 0201)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact972(47776234)
  • Sheba Medical Center ( Site 0200)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact972(35307039)
  • Radboudumc ( Site 0301)
    Nijmegen, Gelderland 6525 GA, Netherlands
    Recruiting
    • Study Coordinator · Contact0243611111
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300)
    Amsterdam, North Holland 1066 CX, Netherlands
    Recruiting
    • Study Coordinator · Contact+31205129111
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2029, 47 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 47 months is close to that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 22, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • MD Anderson Cancer Center ( Site 0104) · Houston, United States
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added
    Show site
    • MD Anderson Cancer Center ( Site 0104) · Houston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07030712
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jul 23, 2025
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion